review Open AccessTop 1% cited
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs
Bioorganic & Medicinal Chemistry Letters · 2015 · Vol. 25(17) · pp. 3420–3435
Concepción Sánchez‐Martínez✉(Eli Lilly (Spain))Lawrence M. Gelbert(Indiana University – Purdue University Indianapolis)Marı́a José Lallena(Eli Lilly (Spain))Alfonso de Dios(Eli Lilly (United States))
Cancer-related Molecular PathwaysAdvanced Breast Cancer TherapiesMicrotubule and mitosis dynamicsCyclin-dependent kinaseCyclin-dependent kinase 6Restriction pointKinaseCyclin-dependent kinase 4ChemistryCell cycleCyclinCyclin-dependent kinase 2Cyclin D
MeSH terms
Antineoplastic AgentsCell CycleHumansNeoplasmsCyclin-Dependent Kinase Inhibitor Proteins
Citations
230
FWCI
10.49
field-weighted impact
References
66
Percentile
99%
vs. same field & year
Citations per year
References
The regulation of E2F by pRB-family proteins
Genes & Development · 1998 · 2,307 citations
Mammalian cyclin-dependent kinases
Trends in Biochemical Sciences · 2005 · 1,281 citations
Mutation and Cancer: Statistical Study of Retinoblastoma
Proceedings of the National Academy of Sciences · 1971 · 7,578 citations
Comprehensive Identification of Cell Cycle–regulated Genes of the Yeast<i>Saccharomyces cerevisiae</i>by Microarray Hybridization
Molecular Biology of the Cell · 1998 · 4,786 citations
Hallmarks of Cancer: The Next Generation
Cell · 2011 · 65,668 citations
Functional Inactivation of the Retinoblastoma Protein Requires Sequential Modification by at Least Two Distinct Cyclin-cdk Complexes
Molecular and Cellular Biology · 1998 · 1,070 citations
Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin‐Dependent Kinases cdc2, cdk2 and cdk5
European Journal of Biochemistry · 1997 · 1,349 citations
Related articles
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs
Bioorganic & Medicinal Chemistry Letters · 2015 · 230 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.